JP2023513073A5 - - Google Patents

Info

Publication number
JP2023513073A5
JP2023513073A5 JP2022546537A JP2022546537A JP2023513073A5 JP 2023513073 A5 JP2023513073 A5 JP 2023513073A5 JP 2022546537 A JP2022546537 A JP 2022546537A JP 2022546537 A JP2022546537 A JP 2022546537A JP 2023513073 A5 JP2023513073 A5 JP 2023513073A5
Authority
JP
Japan
Prior art keywords
composition according
hrsv
glycoprotein
lipids
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022546537A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513073A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/015840 external-priority patent/WO2021155243A1/en
Publication of JP2023513073A publication Critical patent/JP2023513073A/ja
Publication of JP2023513073A5 publication Critical patent/JP2023513073A5/ja
Pending legal-status Critical Current

Links

JP2022546537A 2020-01-30 2021-01-29 呼吸器系ウイルス免疫化組成物 Pending JP2023513073A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062967888P 2020-01-30 2020-01-30
US62/967,888 2020-01-30
PCT/US2021/015840 WO2021155243A1 (en) 2020-01-30 2021-01-29 Respiratory virus immunizing compositions

Publications (2)

Publication Number Publication Date
JP2023513073A JP2023513073A (ja) 2023-03-30
JP2023513073A5 true JP2023513073A5 (cg-RX-API-DMAC10.html) 2024-07-01

Family

ID=77079256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022546537A Pending JP2023513073A (ja) 2020-01-30 2021-01-29 呼吸器系ウイルス免疫化組成物

Country Status (11)

Country Link
US (1) US20230338506A1 (cg-RX-API-DMAC10.html)
EP (1) EP4096683A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023513073A (cg-RX-API-DMAC10.html)
KR (1) KR20220133911A (cg-RX-API-DMAC10.html)
CN (1) CN115103682A (cg-RX-API-DMAC10.html)
AU (1) AU2021214774A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022015053A2 (cg-RX-API-DMAC10.html)
CA (1) CA3169664A1 (cg-RX-API-DMAC10.html)
IL (1) IL295148A (cg-RX-API-DMAC10.html)
MX (1) MX2022009429A (cg-RX-API-DMAC10.html)
WO (1) WO2021155243A1 (cg-RX-API-DMAC10.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
MX2021010075A (es) 2019-02-20 2021-12-10 Modernatx Inc Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales.
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
MX2021011031A (es) 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
CN118490818A (zh) 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
WO2022221336A1 (en) * 2021-04-13 2022-10-20 Modernatx, Inc. Respiratory syncytial virus mrna vaccines
EP4326227A1 (en) 2021-04-23 2024-02-28 ModernaTX, Inc. Stabilized formulations
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN120153078A (zh) * 2022-10-27 2025-06-13 辉瑞大药厂 编码rsv-f的rna分子及含所述rna分子的疫苗
WO2024193965A1 (en) * 2023-03-17 2024-09-26 Glaxosmithkline Biologicals Sa Rsv-f-encoding nucleic acids
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
US20250009865A1 (en) * 2023-05-10 2025-01-09 Sanofi Combination respiratory mrna vaccines
KR20260030125A (ko) * 2023-06-21 2026-03-05 센젠 센신 바이오테크놀로지 컴퍼니 리미티드 호흡기 세포융합 바이러스(rsv) 백신
CN119979573A (zh) * 2023-11-03 2025-05-13 纳美信(上海)生物科技有限公司 一种呼吸道合胞病毒mRNA疫苗
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒(rsv)多肽
CN118064456B (zh) * 2024-03-01 2024-10-29 嘉译生物医药(杭州)有限公司 一种针对人合胞病毒的新型的RSV B mRNA疫苗
WO2025250938A2 (en) 2024-05-31 2025-12-04 Modernatx, Inc. Respiratory syncytial virus and metapneumovirus vaccines
CN121620537A (zh) * 2024-06-19 2026-03-06 厦门万泰沧海生物技术有限公司 Rsv和hmpv融合f蛋白及其用途
CN118480560B (zh) * 2024-07-09 2024-11-26 北京悦康科创医药科技股份有限公司 呼吸道合胞病毒mRNA疫苗及其制备方法和应用
CN120118162B (zh) * 2025-03-07 2026-03-10 深圳华大火眼工程科技有限公司 一种呼吸道合胞病毒的f蛋白突变体、其组合及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176807A1 (en) * 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
EP4421177A3 (en) * 2013-03-13 2024-12-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
DE20164728T1 (de) * 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
US20180271970A1 (en) * 2015-10-22 2018-09-27 Modernatx, Inc. Respiratory syncytial virus vaccine
CN115960263A (zh) * 2016-03-29 2023-04-14 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途
MA46766A (fr) * 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
EP3551193A4 (en) * 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
WO2018170260A1 (en) * 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
EP3606942B1 (en) * 2017-04-04 2025-06-11 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
US11911453B2 (en) * 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
CA3091558A1 (en) * 2018-04-17 2019-10-24 Curevac Ag Novel rsv rna molecules and compositions for vaccination

Similar Documents

Publication Publication Date Title
JP2024503699A5 (cg-RX-API-DMAC10.html)
DE112021000012C5 (de) Coronavirus-Vakzine
US11471525B2 (en) Coronavirus vaccine
JP2024503698A5 (cg-RX-API-DMAC10.html)
US20230302112A1 (en) Respiratory synctial virus rna vaccine
JP2023531511A5 (cg-RX-API-DMAC10.html)
CA2760776C (en) Lipid compositions for the delivery of therapeutic agents
CA2751342C (en) Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
JP2022535006A (ja) 増殖t細胞アッセイ
JP2024514182A5 (cg-RX-API-DMAC10.html)
JPWO2021251453A5 (cg-RX-API-DMAC10.html)
CN116617382B (zh) 新型冠状病毒疫苗及其制备方法和应用
JP2022516356A (ja) 原発性線毛機能不全症の治療のための組成物および方法
KR20250099727A (ko) 호흡기 세포융합 바이러스 rna 백신접종
US12263213B2 (en) Compositions for use in treatment of Chlamydia
WO2024260446A1 (zh) 呼吸道合胞病毒(rsv)疫苗
JP2002512003A (ja) パラミキソウイルスワクチンのためのアルファウイルスベクター
CN118562832A (zh) 编码HTNV包膜糖蛋白GP的基因、其编码的表达载体、mRNA分子及其用途
AU2021244684A1 (en) Compositions and methods for treating and preventing coronaviruses
JP2025510777A5 (cg-RX-API-DMAC10.html)
JPWO2022244815A5 (cg-RX-API-DMAC10.html)
JP2025529906A (ja) コロナウイルスに対するワクチン
CN121057591A (zh) 组合呼吸道mRNA疫苗
JP2025512049A5 (cg-RX-API-DMAC10.html)
WO2025162490A1 (zh) 一种新型mRNA疫苗的制备及其在治疗乙型肝炎病毒疾病药物组合中的应用